Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:12:41.492Z.
Calculation as of: 2026-10-06T22:12:41.492Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e02955ea8e9c2cf4c41ffb6704153fd2748554d2ded3c4943f45d7cf9e8d785e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$16.74M
EBITDA Yield
N/A
TTM Avg
0.54%
3Y Avg
0.35%
5Y Avg
0.35%
Market Cap
$16.52M
EBITDA Yield
N/A
TTM Avg
1.21%
3Y Avg
1.72%
5Y Avg
1.72%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | $16.84M | N/A | N/A | N/A | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | N/A | N/A | N/A | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | N/A | 0.54% | 0.35% | 0.35% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | N/A | N/A | N/A | N/A |
| PAVmed Inc. (PAVM)vs › | $17.07M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | N/A | 1.21% | 1.72% | 1.72% |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A | 6.12% | 6.12% | 6.12% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A | 2.57% | 2.17% | 2.17% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | N/A | 7.50% | 7.48% | 7.48% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
